IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?

被引：21

作者：

Tomala, Jakub ^{[1
]}

Kovar, Marek ^{[1
]}

机构：

[1] Acad Sci Czech Republ, Inst Microbiol, Lab Tumor Immunol, Prague, Czech Republic

来源：

ONCOIMMUNOLOGY | 2016年 / 5卷 / 03期

关键词：

Anti-IL-2; mAb; cancer immunotherapy; IL-2; immunocomplexes; selective stimulatory activity; TUMOR-INFILTRATING LYMPHOCYTES; CD8(+) T-CELLS; ACTIVATED KILLER-CELLS; IN-VIVO EXPANSION; RECOMBINANT INTERLEUKIN-2; SELECTIVE STIMULATION; METASTATIC MELANOMA; ANTITUMOR EFFICACY; COMPLEX TREATMENT; AUTOLOGOUS TUMOR;

D O I：

10.1080/2162402X.2015.1102829

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The in vivo biological activity of IL-2 can be dramatically increased by complexing with anti-IL-2 mAb. Moreover, IL-2/anti-IL-2 mAb immunocomplexes selectively stimulate different subsets of immune cells, depending on the clone of anti-IL-2 mAb that is used. Thus, IL-2/S4B6 mAb complexes strongly stimulate CD122(high) populations, namely NK and memory CD8(+) T cells. They also intermediately stimulate T-reg cells. Conversely, IL-2/JES6.1 mAb immunocomplexes have no stimulatory activity for CD122(high) populations. However, they potently and highly selectively stimulate CD25(+) cells (i.e., T-reg and activated T cells). IL-2/S4B6 mAb immunocomplexes have also been shown to possess antitumor activity in various mouse tumor models.

引用

页数：8